Navigation Links
Going a step Further: Phase IV and Post-Marketing Observational Studies add Value to new Therapies, life Science Webinar Hosted by Xtalks
Date:4/23/2013

Toronto, Canada (PRWEB) April 23, 2013

The intrinsic differences between clinical trials and real-life drug treatment create safety gaps that can undermine the overall benefit for patients and value of marketed drugs.

Post-Approvals Clinical & Epidemiology Studies (PACES), including Post-Marketing Observational Studies (PMOS) and Phase IV studies, are the only sources of information that allows the assessment of real–life effectiveness and safety. These studies are ideal for generating data regarding patient adherence/compliance to treatment and its impact on effectiveness. Practice patterns and adherence to treatment guidelines by physicians can only be assessed with PACES.

In an exciting new webinar, Dr. John Samplis, Chief Scientific Officer at JSS Medical Research Inc., will cover:

  •     The objectives of PMOS and Phase IV studies
  •     Strategies for designing meaningful PMOS and Phase IV studies
  •     Important considerations when conducting PMOS and Phase IV studies, including: Objectives, Study Design, Statistics, Randomization, Non-standardized follow-up, Data Analysis
  •     The advantages and disadvantages of PMOS and Phase IV compared to other post-approval studies design
  •     Examples of PMOS and Phase IV.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit: http://xtks.in/xto591p

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10652903.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
2. Jennifer Aniston's People's Choice Awards Dress Worries Animal Welfare Advocates; Going Green News Site My Cleaning Products Comments It Was a Bad Pick
3. Arnold Schwarzenegger's Climate Change Law Gets Enacted; Going Green News Site Green Bean Cleaning Urges Public to Help It Help Build a Greener Earth
4. Sitting still or going hunting: Which works better?
5. New fuel cell keeps going after the hydrogen runs out
6. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
7. Blocked holes can enhance rather than stop light going through
8. Ceregene Reports Data From Parkinsons Disease Phase 2b Study
9. Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
10. Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):